Curis, Inc. (NASDAQ:CRIS) Sees Significant Drop in Short Interest

Curis, Inc. (NASDAQ:CRIS) was the target of a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 74,100 shares, a decrease of 54.4% from the November 15th total of 162,500 shares. Currently, 1.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 53,500 shares, the short-interest ratio is presently 1.4 days.

Institutional Trading of Curis

Hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Curis by 4.8% in the 1st quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock valued at $2,376,000 after acquiring an additional 10,097 shares during the period. Point72 Asset Management L.P. increased its holdings in shares of Curis by 795.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock valued at $748,000 after acquiring an additional 96,256 shares during the period. Finally, Focused Wealth Management Inc increased its holdings in shares of Curis by 63.1% in the 3rd quarter. Focused Wealth Management Inc now owns 54,066 shares of the biotechnology company’s stock valued at $291,000 after acquiring an additional 20,908 shares during the period. Institutional investors and hedge funds own 29.97% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Curis in a research report on Tuesday.

Curis Price Performance

Shares of NASDAQ CRIS traded down $0.15 during midday trading on Friday, hitting $3.57. The company’s stock had a trading volume of 47,426 shares, compared to its average volume of 42,347. The business’s fifty day simple moving average is $4.50 and its two-hundred day simple moving average is $5.79. Curis has a 1 year low of $3.50 and a 1 year high of $17.49. The firm has a market capitalization of $30.24 million, a price-to-earnings ratio of -0.46 and a beta of 3.34.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.